Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13442966 | 0.91 | HTR6 (0.59) | HTR6ADRA2AHTR2C | |
| SCHEMBL3603320 | 0.91 | HTR6 (0.59) | HTR6ADRA2AHTR2C | |
| SCHEMBL13463207 | 0.82 | HTR6 (0.48) | HTR6ADRA2APKMHTR2CTP53 | |
| SCHEMBL730733 | 0.77 | HTR6 (0.61) | HTR6ADRA2AHTR2C | |
| SCHEMBL750178 | 0.77 | HTR6 (0.61) | HTR6ADRA2AHTR2C | |
| SCHEMBL3647932 | 0.73 | HTR6 (0.59) | HTR6ADRA2AHTR2C | |
| SCHEMBL13442965 | 0.73 | HTR6 (0.59) | HTR6ADRA2AHTR2C | |
| SCHEMBL13463158 | 0.71 | HTR6 (0.51) | HTR6ADRA2APKMHTR2C | |
| SCHEMBL13442971 | 0.70 | HTR6 (0.58) | HTR6ADRA2AHTR2C | |
| SCHEMBL13463183 | 0.70 | HTR6 (0.47) | HTR6ADRA2APKMHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069378-A1 | SUBSTITUTED INDANYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069378-A1 | SUBSTITUTED INDANYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, GPR6 | HTR6 1/4885ADRA2A 43/4885PKM 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.